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Parkinson’s disease (PD) is not a single entity but rather a heterogeneous neurodegenera-
tive disorder.The present study aims to conduct a critical systematic review of the literature
to describe the main pharmacological strategies to treat cognitive dysfunction and major
depressive disorder in PD patients. We performed a search of articles cited in PubMed
from 2004 to 2014 using the following MeSH terms (Medical subject headings) “Parkinson
disease”; “Delirium,” “Dementia,” “Amnestic,” “Cognitive disorders,” and “Parkinson dis-
ease”; “depression,” “major depressive disorder,” “drug therapy.” We found a total of 71
studies related to pharmacological treatment in cognitive dysfunction and 279 studies for
pharmacological treatment in major depressive disorder. After fulfillment of all the inclu-
sion and exclusion criteria, 13 articles remained for cognitive dysfunction and 11 for major
depressive disorder, which are presented and discussed in this study. Further research into
non-motor symptoms of PD may provide insights into mechanisms of neurodegeneration,
and provide better quality of life by using rational drugs.
Keywords: Parkinson’s disease, cognitive disorders, depression, major depressive disorder, dementia, drug therapy,
non-motor symptoms
INTRODUCTION
Parkinson disease (PD) is one of the most complex neurodegen-
erative diseases with a broad spectrum of motor and non-motor
symptoms (1). According to the United Kingdom Parkinson Dis-
ease Society Brain Bank, the clinical diagnosis is based on the
presence of two or three motor features: bradykinesia plus rigidity
or tremor at rest (or both). However, these criteria neither separate
PD from the many other forms of parkinsonism nor contemplates
the non-motor signs. Despite intense research, no effective therapy
is currently available to prevent the onset, or to halt the progression
of the disease.
In PD patients, there is a spectrum of cognitive dysfunc-
tion, ranging from mild cognitive impairment (PD-MCI) to PD
dementia [PDD; (2)]. PD-MCI may represent the earliest stage of
cognitive decline and a risk factor for developing PDD (3). Even
when it is considered to be common, frequency estimates may
vary between studies due to many factors such as differences in
the populations studied (e.g., clinic or community-based; incident
or prevalent of PD), clinical and neuropsychological criteria used,
and the number and type of neuropsychological tests assessed (4).
A comprehensive review of the literature on PD and cognitive
impairment conducted by the movement disorder society (MDS)
task force on PD-MCI demonstrated a mean cross-sectional preva-
lence rate of 26.7% (range 18.9–38.2%) in non-demented patients
(5) and its association with the subsequent development of PDD
(3). The clinical profile of PD-MCI is heterogeneous, with a
broad spectrum of clinical deficits and severity affecting both
non-amnestic and amnestic domains, such as executive function,
psychomotor speed, visuospatial abilities, language, and mem-
ory. Overall, non-amnestic single-domain impairment is the most
affected (4).
Previous studies indicated that executive deficits were more
important predictors of subsequent cognitive decline (6, 7). More
recently, authors of The CamPaIGN study reported a 10-year fol-
low up in patients with PD; they found that a poorer baseline
performance on tests with a posterior cortical basis resulted in
an increased risk for dementia, which leaded to the distinction of
two cognitive syndromes in PD: a “frontal executive” cognitive
deficit, primarily due to dysfunction in dopaminergic frontos-
triatal networks; and a “posterior cortical” cognitive deficit due
to dysfunction in non-dopaminergic systems, which were related
to the development of dementia and characterized by deficits on
semantic fluency and pentagon copying (8). One study supported
by functional imaging, which have reported that patients with
PDD presented with a severe cortical cholinergic deficit in compar-
ison to non-demented PD patients, indicates that the acetylcholine
system is the non-dopaminergic system related to the posterior
cortical subtype and to the progression to dementia (9).
This diverse profile in MCI-PD (evident even in early phases)
characterizes the clinical heterogeneity of cognitive impairment
and its risk for subsequent dementia, being the most affected, the
executive, mnemonic, and visuospatial domains (6, 10, 11).
Another systematic review showed that the prevalence of
dementia among PD subjects, which included a total number
of 1767 PD patients, 554 of them with dementia, was of 24.5%
(95% confidence interval 17.4–31.5%; (12). The clinical profile
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of PDD includes impairment of the attention, memory, language,
visuospatial function, construction, praxis, and executive function
domains. There are some phenomenological differences between
PDD and Alzheimer dementia (AD), particularly in executive
functions, so that a “subcortical” or “dysexecutive” pattern pre-
dominates in PDD. However, these differences are difficult to iden-
tify in the late stages of dementia (13). Neuropathological studies,
therefore, revealed that cortical Lewy body/neuritic pathology is
more extensive and severe in PDD than in PD without dementia
(14). Also, cholinergic deficits occur in PDD, with higher levels in
those with a longer duration of parkinsonism prior to dementia
with lower cortical and limbic Lewy body/neuritic burden (15),
and are ascribed to neuronal loss in basal forebrain choliner-
gic nuclei (15, 16). The presence of cortical cholinergic deficit
in patients with PDD suggests that treatment with cholinesterase
inhibitors may be beneficial (17).
Given the chronic and debilitating nature of PD, it is not
surprising that many patients suffer negative emotional conse-
quences, particularly depression. Other psychiatric symptoms in
PD include sleep disorders, cognitive impairment, psychosis, and
anxiety (18). Reported rates of major depressive disorder in PD
patients vary widely, ranging from 7 to 76% (18). Few scales like
the Beck depression inventory (BDI) and the Geriatric Depression
Scale of Yesavage (GDS) have been validated for the screening of
depression in PD patients, or to assess the severity of it, which
is the case of the Hamilton rating scale for depression (HAMD)
and the Montgomery–Asberg depression rating scale [MADRS;
(19)]. The etiology of depression in PD is thought to be an inter-
action of exogenous causes (e.g., the fact of being diagnosed with
a disabling, chronic disease for which there is no known cure) and
endogenous causes (e.g., dopamine deficiency) (20). As the quality
of life (QoL) in PD patients can be affected by psychiatric symp-
toms, treatment for major depressive disorder in PD is clinically
relevant (21).
Cognitive dysfunction and major depressive disorder are both
recognized entities that can appear simultaneously in any step of
neurodegeneration in PD. Up to day, there are no recommenda-
tions for the optimal treatment for any of these comorbidities
of PD. Here, we evaluate available evidence from clinical stud-
ies to identify the efficacy and safety of available pharmacolog-
ical options to treat cognitive dysfunction and major depressive
disorder in PD.
METHODS
We followed the PRISMA model (Preferred Reporting Items for
Systematic reviews and Meta-Analyses).
ELIGIBILITY CRITERIA
(a) Studies: to evaluate the efficacy and safety of pharmacolog-
ical treatments on cognitive dysfunction and major depres-
sive disorder in PD, we selected clinical trials, cross-sectional
observational studies and case–control studies. However, only
English language articles published from 2004 to 2014 were
included.
(b) Participants: PD patients (>18 years old; both genders) with
diagnostic of cognitive dysfunction or major depressive
disorder according to the DSM-IV (diagnostic and statistical
manual of mental disorders) criteria including depressed
mood or a loss of interest or pleasure in daily activities
for more than 2 weeks (mood represents a change from the
person’s baseline); impaired function (social, occupational,
educational); specific symptoms [at least five of the follow-
ing nine present nearly every day: (1) depressed mood or
irritability most of the day, as indicated by either subjective
report or observation made by others; (2) decreased interest
or pleasure in most activities, most of each day; (3) signif-
icant weight change (5%) or change in appetite; (4) change
in sleep, whether insomnia or hypersomnia; (5) change in
activity; (6) fatigue or loss of energy; (7) guilt/worthlessness;
(8) concentration impairment: diminished ability to think or
concentrate, or more indecisiveness; (9) suicidality: thoughts
of death or having a suicide plan].
(c) Intervention: pharmacological therapy.
(d) Outcome measures: efficacy, safety, and QoL.
SOURCES OF INFORMATION
We included articles from PubMed electronic database updated
until May, 2014. MeSH terms (Medical subject headings) used
for the search were “parkinson disease,” “Delirium,” “Dementia,”
“Amnestic,” “Cognitive disorders,” “depression,” “major depressive
disorder,” and “drug therapy.”
ARTICLE SELECTION
Articles were evaluated by filtering the studies through analysis
of the title, followed by summary and critical analysis of the full
article. To evaluate the methodological quality of the random-
ized clinical trials, we used the CONSORT criteria (Consolidated
Standards of Reporting Trials) available on http://www.consort-
statement.org.
DATA SEARCH
The following data were extracted from the selected articles:
authors, type of study, participant’s characteristics, pharmacologi-
cal intervention, diagnostic criteria, scales, efficacy of intervention,
safety of the intervention, and QoL.
EXCLUSION CRITERIA
Studies without pharmacological treatment strategies were
excluded. The selection and evaluation of the articles were made
by two separated blinded authors.
BIAS RISK ASSESSMENT
We analyzed eligibility criteria for participants of the sample; the
random allocation of participants, the presence of a control group,
the results from the analysis of more than 85% of the sample, the pre-
sentation of results, and the inter group variability of the results.
A sensitivity analysis of included data was not performed.
RESULTS
The search generated a total of 350 studies: 279 related to major
depressive disorder and 71 to cognitive dysfunction. One hun-
dred ninety-nine articles were excluded because of non-focus
on pharmacological intervention; 89 were excluded because of
non-satisfied MeSH selection criteria; 38 were excluded due to a
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poor/non-rigorous study design, publication date, use of other
therapies and/or insufficient data. After all the inclusion and
exclusion criteria were fulfilled, 24 articles remained: 13 for cog-
nitive dysfunction and 11 for major depressive disorder. Those
articles are presented and discussed in this study. The CONSORT
flow diagram is shown in Figure 1.
COGNITIVE DYSFUNCTION AND PARKINSON’S DISEASE
For cognitive dysfunction in PD, 13 articles were analyzed (22–34).
All of them were clinical trials (see Table 1). Neither cross-sectional
observational studies nor case–control studies were found. All,
except one, included patients with PDD. In total, 3853 patients
were studied (see Table 1). All articles were obtained in full-text
version and critically analyzed.
Pharmacological treatments used in these clinical studies were
rivastigmine (3–12 mg) during 24 weeks, rivastigmine (1.5–6 mg)
during 24 weeks, donepezil (5–10 mg) during 20 weeks, donepezil
(5–10 mg) during 24 weeks, galantamine (8–16) during 24 weeks,
memantine (20 mg) during 52 weeks, memantine (20 mg) during
22 weeks, and rasagiline (1 mg) during 12 weeks.
Cognitive dysfunction was defined as impairment in two out
of four cognitive domains in screening neuropsychological tests.
All but two studies used the DSM-IV diagnostic criteria for PDD
(the other two used ICD-10). Seven of eight studies used struc-
tured interviews as mini international neuropsychiatric interview
(MINI) or structured clinical interview (SCI). The main outcomes
were efficacy, safety, and QoL.
To identify the efficacy, all clinical studies evaluated phar-
macological treatment response and improvement of cognitive
dysfunction; nevertheless, the authors used different scales: cog-
nitive subscale of Alzheimer’s disease assessment scale (ADAS-
cog), Alzheimer’s disease cooperative study – clinician’s global
impression of change (ADCS-CGIC), Alzheimer’s disease coop-
erative study activities of daily living (ADCS-ADL), 10-item
neuropsychiatric inventory (NPI-10), mini-mental state exam-
ination (MMSE), computerized assessment system power of
attention tests (CDR), verbal fluency test from the Delis–
Kaplan executive function system (D-KEFS), clinician’s interview-
based impression of change plus caregiver input (CIBIC+;
global function), frontal lobe dysfunction assessment battery
(FAB), neuropsychiatric inventory (NPI-12), disability assess-
ment dementia (DAD), dementia rating scale (DRS), trail making
test (TMT), and nurses observation scale for geriatric patients
(NOS).
FIGURE 1 | Flowchart for articles selection.
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Table 1 | Rational pharmacological approaches for cognitive dysfunction in Parkinson’s disease.
Reference Study Intervention Population Scales used Efficacy Safety Quality of life
Emre
et al. (22)
Clinical
trial
Rivastigmine
3–12 mg/day
541 PDD
patients
ADAS-cog, ADCS-CGIC,
ADCS-ADL, NPI-10, MMSE,
CDR, D-KEFS
Moderate significant efficacy in global ratings of
dementia and cognition (p<0.0005)
AE in 83.7% of patients in
rivastigmine group. Mild to
moderate events
Not evaluated
Poewe
et al. (26)
Clinical
trial
Rivastigmine
1.5–6 mg/day
334 PDD
patients
ADAS-cog, ADCS-ADL, NPI-10,
MMSE, D-KEFS
Improved cognitive performance above baseline
for up to 48 weeks
AE in 75.4% of patients Not evaluated
Burn et al.
(25, 35)
Clinical
trial
Rivastigmine
3–12 mg/day
536 PDD
patients
ADAS-cog, ADCS-CGIC,
ADCS-ADL, D-KEFS, CDR,
MMSE, NPI-10
Greater benefits in patients with visual
hallucinations (p<0.005)
Nausea and vomiting were
the most commonly AE
Not evaluated
Barone
et al. (27)
Clinical
trial
Rivastigmine
7.8–8.4 mg/day
342 PDD
patients
ADAS-cog, ADCS-CGIC,
ADCS-ADL, CDR
Patients with elevated homocysteine levels had
greater effects on cognition (p<0.01)
Severe AE were more
commonly in those with
elevated homocysteine
Not evaluated
Wesnes
et al. (24)
Clinical
trial
Rivastigmine
3–12 mg/day
541 PDD
patients
CDR Improvement on power of attention, continuity of
attention, cognitive reaction time and reaction time
(p<0.01)
Not evaluated Not evaluated
Schmitt
et al. (32)
Clinical
trial
Rivastigmine
3–12 mg/day
402 PDD
patients
D-KEFS Significant effects on tests of letter fluency, card
sorting, and symbol digit modalities (p<0.05)
Not evaluated Not evaluated
Olin
et al. (31)
Clinical
trial
Rivastigmine
3–12 mg/day
402 PDD
patients
ADCS-ADL Modest beneficial effects on basic and higher
level ADL functioning
Not evaluated Not evaluated
Ravina
et al. (23)
Clinical
trial
Donepezil
5–10 mg/day
22 PDD
patients
ADAS-cog, MMSE, DRS Modest effect on cognitive function according to
MMSE
AE in 52% of patients Not evaluated
Dubois
et al. (34)
Clinical
trial
Donepezil
5–10 mg/day
550 PDD
patients
ADAS-cog, CIBIC+ Evidence suggesting cognition and execution
function improvement in Parkinson’s disease
dementia
Higher incidence of adverse
effects in the donepezil
treated groups
Not evaluated
Litvinenko
et al. (28)
Clinical
trial
Galantamine
8–16 mg
41 PDD
patients
MMSE, ADAS-cog, FAB, CDT,
NPI-12, DAD
Positive effects on the overall level of cognitive
impairments assessed on the MMSE and
ADAS-cog scales (p<0.05)
AE in 30% of patients Not evaluated
Litvinenko
et al. (30)
Clinical
trial
Memantine
20 mg/day
62 PDD
patients
MMSE, ADAS-cog, FAB, D-KEFS,
CDR, NPI-12, DAD
Positive effects on the overall level of cognitive
impairments assessed on the MMSE and
ADAS-cog scales (p<0.05)
AE in 3/32 patients Not evaluated
Leroi
et al. (29)
Clinical
trial
Memantine
20 mg/day
25 PDD
patients
DRS, NPI, MMSE, CIBIC-Plus Statically significant benefit on MMSE 1 AE, unlikely to be related
to the study medication
Not evaluated
Hanagasi
et al. (33)
Clinical
trial
Rasagiline
1 mg/day
55 PD-MCI
patients
CDR, Stroop test, TMT A and B Beneficial effects on certain aspects of cognition in
tests of attention and executive functions (p<0.05)
3 AE reported Not evaluated
Parkinson’s disease dementia (PDD), mild cognitive impairment (MCI), adverse events (AE), cognitive subscale of the Alzheimer’s disease assessment scale (ADAS-cog), Alzheimer’s disease cooperative study –
clinician’s global impression of change (ADCS-CGIC), Alzheimer’s disease cooperative study activities of daily living (ADCS-ADL), 10-item neuropsychiatric inventory (NPI-10), mini-mental state examination (MMSE),
computerized assessment system power of attention tests (CDR), verbal fluency test from the Delis–Kaplan executive function system (D-KEFS), clinician’s interview-based impression of change plus caregiver
input (CIBIC+; global function), frontal lobe dysfunction assessment battery (FAB), neuropsychiatric inventory (NPI-12), disability assessment dementia (DAD), dementia rating scale (DRS), trail making test (TMT).
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MAJOR DEPRESSIVE DISORDER AND PARKINSON’S DISEASE
Eleven articles were analyzed (20, 36–45). All of them were clinical
trials (see Table 2). Neither cross-sectional observational studies
nor case–control studies were found. In total, 510 patients were
studied (Table 2). All articles were obtained in full-text version
and critically analyzed.
Pharmacological treatments used in the studies were dulox-
etine (60 mg/day) during 12 weeks, nortriptyline (25–75 mg)
during 8 weeks, paroxetine (continuous release 12.5–37.5 mg)
during 12 weeks, citalopram (10–30 mg/day) during 12 weeks,
Omega-3 (4 capsules/day) during 3 months, escitalopram (20 mg/
day) during 12 weeks, pramipexole (1.5–4.5 mg/day) during
14 weeks, sertraline (50 mg/day) during 14 weeks, reboxetine
(3.75–4.2 mg/day) during 4 months, rasagiline (1–2 mg/day)
during 8 weeks, desipramine (75 mg/day), and citalopram
(20 mg/day) during 14 and 30 days.
All the studies used the DSM-IV major depressive disorder
diagnostic criteria for enrollment patients; 8 of the 11 studies also
used structured interviews as MINI or SCI. The main outcomes to
be measured were efficacy, safety, and QoL.
To identify the efficacy, those clinical studies evaluated the
response to pharmacological treatments and remission of depres-
sion; nevertheless, the authors used different scales: HAMD (clin-
ical response defined as a 50% reduction in baseline to endpoint
score and remission defined as a <8 score), BDI, clinical global
impression-severity (CGI-S), clinical global impression improve-
ment scale (CGI-I), MADRS, inventory of depressive sympto-
matology (IDS), GDS, and the hospital anxiety and depression
scale (HADS). One study evaluated efficacy through brain struc-
tural changes in single-photon emission computed tomography
(SPECT).
Seven articles evaluated the safety of pharmacological therapy.
Side effects were used as outcome measure. To assess the QoL some
studies used the Nottingham quality of life scale (NHP), Parkinson
disease questionnaire (PDQ8), and the short form health survey
(SF-36).
Two clinical trials with PD patients and major depressive dis-
order evaluated the use of selective serotonin reuptake inhibitor
(SSRIs) citalopram at doses of 10–30 mg/day. The treatment
response was measured by cerebral blood flow using SPECT scan.
Larger cortical areas were found to be involved in depressed PD
patients with hyperactivity (reciprocal to basal degeneration in
PD and maybe dopaminergic treatment) and with hypoactiv-
ity (probably due to organic lesions leading to hypoperfusion).
Measurement of monoamines levels, brain-derived neurotrophic
factor (BDNF), orexin-A, interleukin 6 (IL-6), and corticosterone
in the cerebrospinal fluid reported low levels of BDNF and IL-
6. Both studies registered improvement in depressive symptoms
without reporting efficacy, side effects, and QoL. The treatment
response using escitalopram (dose of 20 mg/day) was 37%; depres-
sion remission was 50%; 14% of the population reported side
effects (nausea and confusion), but this study did not report effects
on QoL.
From these 11 studies, 63% reported security. Duloxetine
was the drug that reported higher percentage of side effects
(20.5%). Main side effects were diarrhea, tremor, nausea, vomiting,
drowsiness, syncope, visual hallucinations, decreased libido, and
psychotic symptoms.
One study compared a dopamine agonist (pramipexole) versus
SSRI (sertraline). Patients included in the study showed no motor
symptoms; PD patients with major depressive disorder without
motor symptoms treated with pramipexole had a better treatment
response and remission of the major depressive disorder in 60%
of patients with <10% of side effects compared with sertraline; no
difference was observed in QoL between the two drugs.
Another study tested fatty acids (Omega-3) in combination
with antidepressants: sertraline, tricyclic antidepressants, and tra-
zodone. It found an efficacy >40% compared with the placebo
group.
Treatment with rasagiline (MAO-B) was associated with
improvement in mood, especially at doses of 2 mg. Desipramine
(tricyclic antidepressant) and citalopram (SSRIs) were compared
showing an improvement in the acute treatment on day 14 with
the tricyclic antidepressant and improvement with both antide-
pressants in the 30th, but side effects were reported (bradykinesia
with citalopram, erectile dysfunction, and orthostatic hypotension
with desimipramine).
The analyzed studies, however, did not specify the major
depressive disorder domains in which the drugs had an effect.
DISCUSSION
COGNITIVE DYSFUNCTION
All except one trial included patients with PDD, situation which
reflects the difficulties in designing studies in groups with hetero-
geneous cognitive profiles, such as those seen in MCI-PD and early
stages of PDD.
Although rivastigmine appears to be the most consistent treat-
ment, all clinical trials are from the same population studied by
the same group (22). Even when the study of the same population
allows to compare every clinical trial between each other and to
get more confident conclusions about doses and duration of treat-
ment, those may not be valid to other populations. Taking that
into account, it may be recommendable to conduct clinical trials
in different populations to compare results and to ensure a correct
generalization of the conclusions.
It is important to note that even though the multinational trial
by Dubois et al. with donepezil did not meet its planned primary
objective, the alternative ADAS-cog analysis while removing the
treatment-by-country interaction from the model, revealed a sig-
nificant, dose-dependent benefit with donepezil. Authors attrib-
uted this to possible imbalance in enrollment between participant
countries (34). This finding is consistent with clinical practice,
where caregivers report improvement in cognition of their patients
when donepezil is prescribed.
Patients with PDD were included according to the DSM-IV
criteria (which requires the presence of memory impairment),
and while analyzing the efficacy of treatment, we found that most
primary outcomes were assessed with ADAS-cog (see Table 1), a
scale designed to assess the severity of the major symptoms of
Alzheimer. The main areas of the cognitive domains evaluated
with this scale are memory (50%), language (28%), praxis (14%),
and command understanding (8%) (46); however, this scale lacks
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Table 2 | Rational pharmacological approaches for major depressive disorder in Parkinson’s disease.
Reference Study Intervention Population Scales used Efficacy Safety Quality of life
Bonuccelli
et al. (44)
Clinical
trial
Duloxetine
60 mg
151 Patients HAMD-17, BDI,
CGI-S, PDQ-39
Response (60.4%) and remission
(45.6%)
Adverse events reported in
20.5% of patients
Significant improvement (p<0.001)
on emotional well being, stigma,
cognitive impairment, and bodily
discomfort, as measured by PDQ-39
Dobkin
et al. (43)
Clinical
trial
Nortriptyline
(25–75 mg),
paroxetine
(12.5–37.5 mg)
52 Patients:
paroxetine 18,
nortriptyline 17,
placebo 17
HAMD-17, CGI-I,
HAMA
Response to acute treatment in 16
patients: paroxetine (3), nortriptyline
(9), placebo (4)
Not evaluated Not evaluated
Palhagen
et al. (42)
Clinical
trial
Citalopram
10–30 mg/day
37 Patients: PD+MD
(11), PD (14), MD (12)
HAMD-17,
MADRS
Modest effect on cognitive function
according to MMSE
Not evaluated Not evaluated
Palhagen
et al. (40)
Clinical
trial
Citalopram
10–30 mg/day
37 Patients: PD+MD
(11), PD (14), MD (12)
HAMD-17,
MADR, SPECT
Expected decrease in the 5 HIAA and
MHPG levels in patients with solely
MD, but not in PD patients with MD.
Levels of BDNF and IL-6 were lower in
the PD patients
Not evaluated Not evaluated
Da Silva
et al. (20)
Clinical
trial
Omega-3 4
capsules
17 Patients: Omega-3
(7), placebo (10)
MADRS, BDI,
CGI
Positive effects on the overall level of
cognitive impairments assessed on the
MMSE and ADAS-cog scales (p<0.05)
Not evaluated Not evaluated
Weintraub
et al. (38)
Clinical
trial
Escitalopram
20 mg
14 Patients HAMD, IS, CGI-I 42% of patients responded Adverse events reported in
2 patients (nausea and
confusion)
Not evaluated
Barone
et al. (36)
Clinical
trial
Pramipexole
1.5–4.5 mg/day,
sertraline
50 mg/day
67 Patients HAMD-17, SF-36 Larger cortical areas were found to be
involved in depressed PD patients,
both with hyperactivity and with
hypoactivity
Adverse events reported in
3 patients on the pramipexole
group and in 8 on the
sertraline group
General improvement for both
groups
Pintor
et al. (37)
Clinical
trial
Reboxetine
3.74–4.2 mg/day
17 Patients HAMD, GDS,
HADS, NHP
Improvement of 50% at the HAMD
scores in 12 patients. HAD mean
scores decreased by 59.34 and
52.01% at the GDS.
Adverse events reported in 2
patients (vertigo and redness)
Mean scores on the NHP
decreased by 44.59%
Korchounov
et al. (45)
Clinical
trial
Rasagiline
1–2 mg/day
6 Patients HAMD-17 Subjects treated with 2 mg/d scored
<14 after treatment at HDRS score
Adverse effects or insomnia
were not reported
Improvement was more
pronounced if treated with 2 mg
of rasagiline (p = 0.20)
(Continued)
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specificity for PDD due to obvious differences in the profiles of
these two conditions; the predominance of memory impairment
in the first one and the “dysexecutive” impairment on the second
one. The fact that patients were included with the DSM-IV criteria
and that the instrument utilized to assess the primary end point
of efficacy was the ADAS-cog makes that the results of the studies
focused mainly in domains usually affected in Alzheimer’s disease
but not in those related with the cognitive profile in PDD.
Comparative studies used in the task force for clinical diag-
nostic criteria for dementia associated with Parkinson’s disease
matched dementia on the basis of the DRS. Therefore, it has been
suggested as an alternative to assess efficacy in clinical trials with
cholinesterase inhibitors for PDD, given its sensitivity for the diag-
nosis of executive dysfunction (47). This scale was used as a part
of the secondary objective in two studies of the current review.
Task force has made recommendations about the test for use in
the diagnosis of PDD (48) and PD-MCI (2). Measures specific
to PD have the advantage that they emphasize testing cogni-
tive deficits associated with PD (e.g., executive and visuospatial
deficits) whereas generic measures tend to focus on memory abili-
ties. Scales designed to asses cognitive impairment associated with
PD include the Parkinson’s disease dementia – short screen (PDD-
SS) (49), the Parkinson neuropsychiatric dementia assessment
(PANDA) (50), the mini-mental Parkinson (MMP) (51), the scales
for outcomes of Parkinson’s disease – cognition (SCOPA-Cog)
(52), and the Parkinson’s disease cognitive rating scale (PD-CRS)
(53). All of them with good diagnostic accuracy and some need a
minimum of time for administration. Formal assessment of each
domain requires more detailed neuropsychological tests. Future
studies will benefit from using these ones and will allow more
definitive conclusions.
When conducting clinical trials about treatment for cognitive
dysfunction, it is important to take into account the presence
of neuropsychiatric symptoms; depression, apathy, anxiety, and
irritability, are frequent in non-demented PD patients (54). The
first two can affect the cognitive performance on neuropsycholog-
ical tests since they have been negatively associated with executive
functioning and with immediate memory (55). Although not all,
most of the studies of the current review, state that the presence
of depression was an exclusion criterion, partly eliminating in this
way potential sources of confusion.
The association between cognitive dysfunction and depres-
sive symptoms has a possible underlying mechanism in common,
which in some studies has been related to acetylcholine. In this
respect, Bohnen et al. demonstrated a significant inverse corre-
lation between cortical AChE activity and the scores of the Cor-
nell scale for depression in dementia. This correlation remained
significant after controlling for mini-mental state examination
scores (56). Moreover, Meyer et al. reported in vivo reductions of
α4β2 nAChRs in PD that correlated with both increased severity
of depressive symptoms and severity of cognitive symptoms (57).
Studies indicate that the clinical phenotype is also associated
with dementia, patients with a tremor-dominant phenotype are
rare to present dementia (58), while in patients with axial symp-
toms dementia is developed earlier in the course of the disease
(35). Moreover, in a recent meta-analysis, patients with non-
tremor predominant motor symptoms had more severe cognitive
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impairments than tremor-dominant patients. Results of this study
also suggested that PD subgroups with depression had more severe
cognitive impairment. Because of the influence of depression
and the subtype of predominant motor symptoms on cognition
authors consider important to take them into account when eval-
uating a cognitive profile in PD (59). It would be interesting
to determine if certain clinical phenotype benefits more from
therapy, which also could indicate or reinforce the implicated
mechanisms of cognitive dysfunction in these patients.
Nevertheless, none of the studies assessed QoL (see Table 1).
QoL is nowadays considered a unique and irreplaceable assess-
ment for clinical evaluation. Instead of QoL, the ADCS-ADL
scale was used. This scale can indirectly quantify the QoL of
patients and care givers. However, the activities assessed by the
scale can be related to both, cognitive impairment and motor
symptoms, which can be a confounder if appropriate measures
are not taken.
Although the unified Parkinson’s disease rating scale (UPDRS)
was assessed before and after each study, the ON/OFF status of the
patient is not mentioned during the neuropsychological assess-
ment of the patient, which can influence the scores that require
motor responses.
Unfortunately, only one study included patients with PD-MCI,
it revealed that rasagiline may confer some beneficial effects on
certain aspects of cognition in this patient population (33). The
relevance of the PD-MCI as a risk factor for the development of
PDD, makes this study a start point for future studies aiming to
treat and prevent PDD. New clinical criteria for diagnosing PD-
MCI will allow uniform inclusion for PD patients’ in new clinical
trials.
In spite of this limitations, studies showed benefit in the pri-
mary endpoint for rivastigmine and if removing the treatment-by-
country interaction, also for donepezil. A recent study assessing the
efficacy of cholinestarease inhibitors in PDD, MCI-PD, and Lewy
body dementia concluded that the beneficial effect on cognitive
function was observed in both the donepezil and rivastigmine
groups (SMD −0.42, 95% CI −0.58 to −0.25, p< 0.00001; SMD
−0.27, 95% CI−0.44 to−0.11, p< 0.001, respectively) (60).
In the near future, it would be interesting to conduct functional
studies in combination with biomarkers in order to determine
additional mechanisms for PDD.
MAJOR DEPRESSIVE DISORDER
All articles reviewed in this study aimed to treat major depres-
sive disorder in PD patients mainly by the use of SSRIs antide-
pressants. This type of antidepressants is often used in clinical
practice, despite possible side effects as nausea, vomiting, sexual
dysfunction, diarrhea, and auditory hallucinations (21).
Two clinical trials included in this review reported response to
citalopram treatment measured by cerebral blood flow by SPECT
(40) and monoamine levels, BDNF, orexin-A, IL-6, and corticos-
terone in the cerebrospinal fluid (42), but did not study side effects.
These studies only reported an improvement in depressive symp-
toms without outcome measures as efficacy, side effects or QoL
(see Table 2). One study reported side effects with citalopram
(bradykinesia) (39).
A study treating patients with dopamine agonists reported a
reduction of depression symptoms; however, the mechanism of
this reduction is not clear (36). We could suggest an indirect effect
associated with improvement on motor symptoms. The authors
compared pramipexole with sertraline to treat major depressive
disorder in PD patients without history of motor symptoms. The
pramipexole group had a greater response to treatment, remission
of depression symptoms, and fewer side effects compared with the
sertraline group (36).
The antidepressant effect of rasagiline was obtained with higher
doses than those used for motor control symptoms (1 mg/day).
The authors suggesting that the improvement in mood is not a
direct result of the improvement in motor function.
Selective serotonin reuptake inhibitor, serotonin–norepinephrine
reuptake inhibitors (SNRIs), selective noradrenaline recapture
inhibitor, and tricyclic antidepressants (TCAs) seem to be a good
strategy to treat PD patients. Nevertheless, the non-homogeneous
methodology used in the studies to assess outcome measures and
the limited number of studies focused on these drugs complicate
a statistical analysis and getting a conclusion by a meta-analysis.
SSRIs are the most studied drugs, reporting a high rate of response
to treatment and remission of the symptoms associated with major
depressive disorder (21). The American Academy of Neurology
declared that there is insufficient evidence to recommend specific
antidepressant treatments for major depression disorder in PD
patients (61). Considering that this is a chronic and severe disabil-
ity condition, the economic impact for the patient suffering from
this condition is high. Therefore, the development of a treatment
guideline for patients with PD and major depressive disorder is
necessary.
CONCLUSION
Here, we ask the question “are these current pharmacological
strategies safe and efficient to treat cognitive dysfunction and
depression in Parkinson’s disease?”
Unfortunately not! There is insufficient evidence to recom-
mend specific pharmacological treatment for these non-motor
symptoms of PD. Therefore, there is the need to conduct more
clinical studies.
Finally, we must remember that, however, exciting the neurobi-
ological mechanisms might be, the clinical usefulness of rational
therapeutic approaches will be determined by their ability to pro-
vide efficacy, safety, long-lasting, and substantial improvements
in QoL.
Most of the studies of cognitive dysfunction in Parkinson have
been conducted in patients with dementia; however, the different
prognosis in syndromes of cognitive impairment makes manda-
tory to develop studies since these stages where clinical trials are
lacking.
Early MCI and PDD differences in cognitive profile will allow
that disease modifying therapies may be targeted at the differ-
ent dopaminergic and non-dopaminergic mechanisms involved
in the pathophysiology of cognitive dysfunction in patients with
Parkinson’s disease.
It is necessary to design clinical trials according to criteria and
end point measures specifically designed for MCI-PD and PDD,
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which will allow more definitive conclusions and understanding
in this topic.
ACKNOWLEDGMENTS
We would like to thank the colleagues working at the “Unidad
de Trastornos del Movimiento y Sueño (TMS)” from Hospital
General Dr. Manuel Gea González and Hospital General Ajusco
Medio. We sincerely thank the founding from “Secretaría de Cien-
cia, Tecnología e Innovación (SECITI)”. OA-C is supported by
CONACYT-BMBF 2013 (Grant 208132).
REFERENCES
1. Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, et al. Chang-
ing the research criteria for the diagnosis of Parkinson’s disease: obstacles and
opportunities. Lancet Neurol (2013) 12:514–24. doi:10.1016/S1474-4422(13)
70047-4
2. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC,
et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease:
movement disorder society task force guidelines. Mov Disord (2012) 27:349–56.
doi:10.1002/mds.24893
3. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive
impairment in Parkinson’s disease: progression to dementia. Mov Disord (2006)
21:1343–9. doi:10.1002/mds.20974
4. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson’s disease. Min-
erva Med (2011) 102:441–59.
5. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al.
MDS task force on mild cognitive impairment in Parkinson’s disease: critical
review of PD-MCI. Mov Disord (2011) 26:1814–24. doi:10.1002/mds.23823
6. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neu-
ropsychological prediction of dementia in Parkinson’s disease. J Neurol Neuro-
surg Psychiatry (1998) 64:178–83. doi:10.1136/jnnp.64.2.178
7. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkin-
son’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry
Neurol (2005) 18:149–54. doi:10.1177/0891988705277540
8. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al.
The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident
population-based cohort. J Neurol Neurosurg Psychiatry (2013) 84:1258–64.
doi:10.1136/jnnp-2013-305277
9. Hilker R, Thomas AV, Klein JC,Weisenbach S, Kalbe E, Burghaus L, et al. Demen-
tia in Parkinson disease: functional imaging of cholinergic and dopaminer-
gic pathways. Neurology (2005) 65:1716–22. doi:10.1212/01.wnl.0000191154.
78131.f6
10. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, et al. Memory and
executive function impairment predict dementia in Parkinson’s disease. Mov
Disord (2002) 17:1221–6. doi:10.1002/mds.10280
11. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects
with Parkinson’s disease in the United Kingdom. Mov Disord (2004) 19:1043–9.
doi:10.1002/mds.20216
12. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of
dementia in Parkinson’s disease. Mov Disord (2005) 20:1255–63. doi:10.1002/
mds.20527
13. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical
diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord
(2007) 22:1689–707. doi:10.1002/mds.21507
14. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence
of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci (2013)
14:626–36. doi:10.1038/nrn3549
15. Ballard C, Ziabreva I, Perry R, Larsen JP, O’Brien J, Mckeith I, et al. Differences
in neuropathologic characteristics across the Lewy body dementia spectrum.
Neurology (2006) 67:1931–4. doi:10.1212/01.wnl.0000249130.63615.cc
16. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, et al. Cholin-
ergic correlates of cognitive impairment in Parkinson’s disease: comparisons
with Alzheimer’s disease. J Neurol Neurosurg Psychiatry (1985) 48:413–21.
doi:10.1136/jnnp.48.5.413
17. Cummings JL. Cholinesterase inhibitors for treatment of dementia associ-
ated with Parkinson’s disease. J Neurol Neurosurg Psychiatry (2005) 76:903–4.
doi:10.1136/jnnp.2004.061499
18. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME. Prevalence and treatment
of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci (2005)
17:310–23. doi:10.1176/appi.neuropsych.17.3.310
19. Vanderheyden JE, Gonce M, Bourgeois P, Cras P, De Nayer AR, Flamez A, et al.
Epidemiology of major depression in Belgian parkinsonian patients.ActaNeurol
Belg (2010) 110:148–56.
20. Da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R,
et al. Depression in Parkinson’s disease: a double-blind, randomized, placebo-
controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord
(2008) 111:351–9. doi:10.1016/j.jad.2008.03.008
21. Hagikura M, Iwamoto K, Aleksic B, Ozaki N. What is a rational antidepressant
treatment for major depression in patients with Parkinson’s disease? Psychiatry
Clin Neurosci (2012) 66:463. doi:10.1111/j.1440-1819.2012.02362.x
22. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al.
Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med
(2004) 351:2509–18. doi:10.1056/NEJMoa041470
23. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil
for dementia in Parkinson’s disease: a randomised, double blind, placebo
controlled, crossover study. J Neurol Neurosurg Psychiatry (2005) 76:934–9.
doi:10.1136/jnnp.2004.050682
24. Wesnes KA, Mckeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine
on attention in dementia associated with Parkinson disease. Neurology (2005)
65:1654–6. doi:10.1212/01.wnl.0000184517.69816.e9
25. Burn D, Emre M, Mckeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of
rivastigmine in patients with and without visual hallucinations in dementia
associated with Parkinson’s disease. Mov Disord (2006) 21:1899–907. doi:10.
1002/mds.21077
26. Poewe W,Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits
of rivastigmine in dementia associated with Parkinson’s disease: an active treat-
ment extension study. Mov Disord (2006) 21:456–61. doi:10.1002/mds.20700
27. Barone P, Burn DJ, Van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus
placebo in hyperhomocysteinemic Parkinson’s disease dementia patients. Mov
Disord (2008) 23:1532–40. doi:10.1002/mds.21997
28. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of
galantamine (reminyl) for dementia in patients with Parkinson’s disease (an
open controlled trial). Neurosci Behav Physiol (2008) 38:937–45. doi:10.1007/
s11055-008-9077-3
29. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of
memantine in dementia associated with Parkinson’s disease. Mov Disord (2009)
24:1217–21. doi:10.1002/mds.22495
30. Litvinenko IV, Odinak MM, Mogil’naya VI, Perstnev SV. Use of meman-
tine (akatinol) for the correction of cognitive impairments in Parkinson’s
disease complicated by dementia. Neurosci Behav Physiol (2010) 40:149–55.
doi:10.1007/s11055-009-9244-1
31. Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associ-
ated with Parkinson’s disease: effects on activities of daily living. Dement Geriatr
Cogn Disord (2010) 29:510–5. doi:10.1159/000305100
32. Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on
executive function in patients with Parkinson’s disease dementia. CNS Neurosci
Ther (2010) 16:330–6. doi:10.1111/j.1755-5949.2010.00182.x
33. Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, et al.
The effects of rasagiline on cognitive deficits in Parkinson’s disease patients
without dementia: a randomized, double-blind, placebo-controlled, multicenter
study. Mov Disord (2011) 26:1851–8. doi:10.1002/mds.23738
34. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G,
et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind
efficacy and safety study. Mov Disord (2012) 27:1230–8. doi:10.1002/mds.25098
35. Burn DJ, Rowan EN,Allan LM, Molloy S, O’Brien JT, Mckeith IG. Motor subtype
and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia,
and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2006) 77:585–9.
doi:10.1136/jnnp.2005.081711
36. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al.
Pramipexole versus sertraline in the treatment of depression in Parkinson’s dis-
ease: a national multicenter parallel-group randomized study. J Neurol (2006)
253:601–7. doi:10.1007/s00415-006-0067-5
37. Pintor L, Bailles E, Valldeoriola F, Tolosa E, Marti MJ, De Pablo J. Response
to 4-month treatment with reboxetine in Parkinson’s disease patients with a
major depressive episode. Gen Hosp Psychiatry (2006) 28:59–64. doi:10.1016/j.
genhosppsych.2005.07.005
www.frontiersin.org March 2015 | Volume 6 | Article 71 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sandoval-Rincón et al. Cognitive dysfunction and depression in Parkinson’s disease
38. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Esci-
talopram for major depression in Parkinson’s disease: an open-label, flexible-
dosage study. J Neuropsychiatry Clin Neurosci (2006) 18:377–83. doi:10.1176/
appi.neuropsych.18.3.377
39. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Compar-
ison of desipramine and citalopram treatments for depression in Parkinson’s dis-
ease: a double-blind, randomized, placebo-controlled study. Mov Disord (2008)
23:850–7. doi:10.1002/mds.21966
40. Palhagen SE, Carlsson M, Curman E, Walinder J, Granerus AK. Depressive
illness in Parkinson’s disease – indication of a more advanced and wide-
spread neurodegenerative process? Acta Neurol Scand (2008) 117:295–304.
doi:10.1111/j.1600-0404.2007.00986.x
41. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. The
impact of treatment of depression on quality of life, disability and relapse in
patients with Parkinson’s disease. Mov Disord (2009) 24:1325–32. doi:10.1002/
mds.22586
42. Palhagen S, Qi H, Martensson B, Walinder J, Granerus AK, Svenningsson P.
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkin-
son’s disease and major depression. J Neurol (2010) 257:524–32. doi:10.1007/
s00415-009-5353-6
43. Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, et al. Depres-
sion in Parkinson’s disease: symptom improvement and residual symptoms after
acute pharmacologic management. Am J Geriatr Psychiatry (2011) 19:222–9.
doi:10.1097/JGP.0b013e3181e448f7
44. Bonuccelli U, Meco G, Fabbrini G, Tessitore A, Pierantozzi M, Stocchi F, et al.
A non-comparative assessment of tolerability and efficacy of duloxetine in the
treatment of depressed patients with Parkinson’s disease. Expert Opin Pharma-
cother (2012) 13:2269–80. doi:10.1517/14656566.2012.736490
45. Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on
motor function and depression in de novo PD. Clin Neuropharmacol (2012)
35:121–4. doi:10.1097/WNF.0b013e31823b1da8
46. Mohs RC, Rosen WG, Davis KL. The Alzheimer’s disease assessment scale:
an instrument for assessing treatment efficacy. Psychopharmacol Bull (1983)
19:448–50.
47. Dujardin K, Devos D, Duhem S, Destee A, Marie RM, Durif F, et al. Util-
ity of the Mattis dementia rating scale to assess the efficacy of rivastigmine
in dementia associated with Parkinson’s disease. J Neurol (2006) 253:1154–9.
doi:10.1007/s00415-006-0175-2
48. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diag-
nostic procedures for Parkinson’s disease dementia: recommendations from
the movement disorder society task force. Mov Disord (2007) 22:2314–24.
doi:10.1002/mds.21844
49. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B,
Martinez-Corral M, et al. PDD-short screen: a brief cognitive test for screening
dementia in Parkinson’s disease.MovDisord (2010) 25:440–6. doi:10.1002/mds.
22877
50. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, et al.
Screening for cognitive deficits in Parkinson’s disease with the Parkinson
neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism
Relat Disord (2008) 14:93–101. doi:10.1016/j.parkreldis.2007.06.008
51. Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A.
Mini-mental Parkinson: first validation study of a new bedside test con-
structed for Parkinson’s disease. Behav Neurol (1995) 8:15–22. doi:10.3233/
BEN-1995-8102
52. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout
AM, et al. Assessment of cognition in Parkinson’s disease. Neurology (2003)
61:1222–8. doi:10.1212/01.WNL.0000091864.39702.1C
53. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano
B, Gironell A. Parkinson’s disease-cognitive rating scale: a new cognitive scale
specific for Parkinson’s disease. Mov Disord (2008) 23:998–1005. doi:10.1002/
mds.22007
54. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell
A, Trapecio Group S. Prevalence and correlates of neuropsychiatric symp-
toms in Parkinson’s disease without dementia. Mov Disord (2008) 23:1889–96.
doi:10.1002/mds.22246
55. Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The inde-
pendent influence of apathy and depression on cognitive functioning in Parkin-
son’s disease. Neuropsychology (2010) 24:721–30. doi:10.1037/a0019650
56. Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore
RY. Cortical cholinergic denervation is associated with depressive symptoms in
Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry
(2007) 78:641–3. doi:10.1136/jnnp.2006.100073
57. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced
alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to
mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychi-
atry (2009) 66:866–77. doi:10.1001/archgenpsychiatry.2009.106
58. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor
subtype and risk for incident dementia in Parkinson’s disease.MovDisord (2006)
21:1123–30. doi:10.1002/mds.20897
59. Tremblay C, Achim AM, Macoir J, Monetta L. The heterogeneity of cognitive
symptoms in Parkinson’s disease: a meta-analysis. J Neurol Neurosurg Psychiatry
(2013) 84:1265–72. doi:10.1136/jnnp-2013-305021
60. Rolinski M, Fox C, Maidment I, Mcshane R. Cholinesterase inhibitors for
dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impair-
ment in Parkinson’s disease. Cochrane Database Syst Rev (2012) 3:CD006504.
doi:10.1002/14651858.CD006504.pub2
61. Pae CU. Comments on ‘what is a rational antidepressant treatment for major
depression in patients with Parkinson’s disease?’. Psychiatry Clin Neurosci (2013)
67:65–6. doi:10.1111/pcn.12009
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 31 October 2014; accepted: 16March 2015; published online: 31March 2015.
Citation: Sandoval-Rincón M, Sáenz-Farret M, Miguel-Puga A, Micheli F and Arias-
Carrión O (2015) Rational pharmacological approaches for cognitive dysfunction and
depression in Parkinson’s disease. Front. Neurol. 6:71. doi: 10.3389/fneur.2015.00071
This article was submitted to Movement Disorders, a section of the journal Frontiers in
Neurology.
Copyright © 2015 Sandoval-Rincón, Sáenz-Farret , Miguel-Puga, Micheli and Arias-
Carrión. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Neurology | Movement Disorders March 2015 | Volume 6 | Article 71 | 10
